Literature DB >> 29794808

Acromegalic Cardiomyopathy: An Overview of Risk Factors, Clinical Manifestations, and Therapeutic Options.

Michael D Goldberg1, Natasha Vadera2, Srikanth Yandrapalli3, William H Frishman3.   

Abstract

Acromegaly is a rare endocrine disorder that carries a significant burden of cardiovascular morbidity and mortality. Abnormalities of the growth hormone/insulin-like growth factor-1 axis in acromegaly lead to the characteristic cardiovascular manifestations of this disease. One hallmark feature of the disease is acromegalic cardiomyopathy, a syndrome of progressive cardiac dysfunction characterized by left ventricular hypertrophy, diastolic dysfunction, and combined systolic and diastolic dysfunction in the very advanced stage. In this article, we review the current concepts regarding the pathophysiology of acromegalic cardiomyopathy and discuss the various risk factors for its development. We also explore the question of whether the alterations in cardiac function are reversible with successful biochemical control of growth hormone excess either medically or surgically.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29794808     DOI: 10.1097/CRD.0000000000000215

Source DB:  PubMed          Journal:  Cardiol Rev        ISSN: 1061-5377            Impact factor:   2.644


  4 in total

1.  Assessment of fragmented QRS formation and its relationship with left ventricular hypertrophy in nonhypertensive acromegaly patients

Authors:  Muhammet Dural; Göknur Yorulmaz; Elif Sevil Alagüney; Kadir Uğur Mert; Ezgi Çamli; Ahmet Toygar Kalkan; Aysen Akalin; Nur Kebapçi; Ahmet Serdar Yilmaz; Selda Murat; Belgin Efe
Journal:  Turk J Med Sci       Date:  2021-10-21       Impact factor: 0.973

2.  Effects of recombinant human growth hormone treatment on growth, body composition, and safety in infants or toddlers with Prader-Willi syndrome: a randomized, active-controlled trial.

Authors:  Aram Yang; Jin-Ho Choi; Young Bae Sohn; Yunae Eom; Jiyoon Lee; Han-Wook Yoo; Dong-Kyu Jin
Journal:  Orphanet J Rare Dis       Date:  2019-09-11       Impact factor: 4.123

Review 3.  Acromegaly, inflammation and cardiovascular disease: a review.

Authors:  Thalijn L C Wolters; Mihai G Netea; Niels P Riksen; Adrianus R M M Hermus; Romana T Netea-Maier
Journal:  Rev Endocr Metab Disord       Date:  2020-12       Impact factor: 6.514

4.  Subclinical Ventricular Dysfunction in Long-Term Acromegaly Assessed by Speckle-Tracking Echocardiography.

Authors:  Patricia Gadelha; Eduardo C L Santos; Jose Castillo; Lucio Vilar
Journal:  Front Endocrinol (Lausanne)       Date:  2022-02-04       Impact factor: 5.555

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.